knowledge -WSS

knowledge

author：explore 2025-08-12 09:12:37 - browse：78

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Medicare Advantage isn’t working — for anyone

leisure time

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Doctor of U.S. President Joe Biden says he is fit for duty

ASCO eve: Let’s set the table for this year's meeting

'Vaccine

Elisabeth Bik tackles the widespread issue of research misconduct

Medicare isn't yet testing food as medicine

focus

knowledge

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ASCO eve: Let’s set the table for this year's meeting

DIEP, the 'gold standard' of breast reconstruction, is under threat

H5N1 virus can be tracked in retail milk, scientists say

Bright Health sells Medicare Advantage business to Molina

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

How to save PrEP access — and even expand it

Are embryos people? Reproductive medicine's future depends on the answer

In age of alternative facts, a scholarly course on calling out crap

Investigation reveals sickle cell patients pressured into sterilizations

leisure time

Laying a path for careers in science

Study fuels hope CAR

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Bird flu surveillance in wastewater gets boost from consortium

Fentanyl is making it harder to start addiction treatment

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

explore

focus

leisure time

hotspot